Software as a medical devices (SaMD) market is estimated to reach at a CAGR of 69.31% during the forecast period (2024-2031).
Software as a Medical Device (SaMD) refers to software intended for medical purposes without being part of a physical medical device. SaMD can perform functions such as diagnosing diseases, monitoring patient conditions, and supporting clinical decisions. It is widely used in digital health applications, including AI-driven diagnostics, mobile health (mHealth) apps, and remote patient monitoring. The global SaMD market is experiencing significant growth, driven by advancements in artificial intelligence, increasing regulatory approvals, and the rising adoption of digital healthcare solutions. With growing investments in healthcare technology and the need for efficient, data-driven medical solutions, the SaMD market is expected to expand rapidly in the coming years.
Download Free Sample PDF: https://www.datamintelligence.com/download-sample/software-as-a-medical-devices-market
Market Growth Drivers:
The growth of the Software as a Medical Device (SaMD) market is primarily driven by frequent product launches and the increasing adoption of IoT and connected devices in healthcare. Additionally, streamlined regulatory processes for SaMD certification and rising investments from companies are expected to further propel market expansion.
The widespread integration of IoT in healthcare is anticipated to play a crucial role in SaMD market growth over the forecast period. Smart devices, including sensors, wearables, and smartphones, collect critical health data, enhancing patient care and experience. The rising demand for data analytics and real-time monitoring is fueling IoT adoption, with applications such as continuous tracking of vital signs, remote patient monitoring, and chronic disease management. For example, in 2018, the FDA approved electroCore, Inc.’s gammaCore Sapphire device for acute migraine treatment, followed by its approval in 2020 for preventive migraine care. Furthermore, in February 2020, Cisco expanded its IoT portfolio to support service providers in optimizing cellular IoT and 5G use cases, paving the way for advanced healthcare applications.
However, concerns over patient data privacy pose a significant challenge to market growth. The increasing risk of data breaches, coupled with the absence of stringent regulations for health data protection, has raised concerns among users regarding the security of sensitive medical information. These privacy risks may hinder the widespread adoption of SaMD technologies in the coming years.
Market Segments:
By Device Type: Wearable Device, PCs/Laptop, Smartphone/tablets
By Application: Diagnostic, Clinical Management
By Deployment Method: Cloud-based, On-Premise
Competitive Landscape
- Paragon Biosciences (Qlarity Imaging LLC)
- Arterys Inc
- Viz.ai, Inc
- Apple Inc
- iSchemaView, inc. (RAPID)
- MaxQ AI Ltd
- Greenfinch Technology
- Siemens Healthineers AG
- Koninklijke Philips N.V.
- VitalConnect
Customize Your Scope: https://www.datamintelligence.com/customize/software-as-a-medical-devices-market
Regional Growth
North America Dominates the Software as a Medical Device Market
North America is expected to maintain the largest market share in the global Software as a Medical Device (SaMD) market, driven by increasing FDA approvals for software-based medical solutions and substantial investments in the healthcare sector by key countries like the U.S. and Canada. For instance, in July 2020, Channel Medsystems received FDA clearance for its next-generation Cerene Cryotherapy device for treating menstrual bleeding. Additionally, in May 2020, Arterys Inc. secured $28 million in Series C funding to advance AI-driven medical solutions globally. This investment round, led by Benslie Investment Group and Temasek Holdings, also included contributions from Fosun, Revelation Partners, Emergent Medical Partners, and Varian Medical Systems, further strengthening North America’s leadership in the SaMD market.
Key Development:
On August 2, 2021, Qlarity Imaging and Blackford announced a strategic partnership to expand the availability of QuantX Diagnostic AI, an advanced artificial intelligence-based tool designed to assist breast radiologists in detecting and diagnosing breast cancer with greater accuracy. Through this collaboration, QuantX, the first-ever FDA-cleared AI-driven software for breast cancer diagnosis, became accessible to a broader network of radiologists via the Blackford Platform, a leading provider of AI-powered medical imaging solutions.
For Detailed Report: https://www.datamintelligence.com/enquiry/software-as-a-medical-devices-market
